At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 10, 2026 at 05:30 ET
MiNK Therapeutics (INKT) announced a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers, supported by approximately $1.1 million in non-dilutive funding for IND-enabling development. The deal includes a double-digit percentage share of future commercial revenues and leverages MiNK's allogeneic, off-the-shelf iNKT platform to address high-unmet-need pediatric malignancies.
- MiNK Therapeutics secured ~$1.1 million in non-dilutive funding from C-Further to advance PRAME-TCR-iNKT therapy through IND-enabling studies.
- The collaboration includes a meaningful double-digit percentage of downstream commercial revenue, preserving MiNK's long-term value capture.
- Program is non-exclusive, allowing MiNK to retain full rights to its iNKT platform and pursue other indications and partnerships.
- University of Southampton will conduct independent preclinical studies to nominate a lead clinical candidate for first-in-human trials in children.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access